Can Artificial Intelligence Diagnose Skin Lesions? With Philipp Tschandl, MD, PhD

​ Philipp Tschandl, MD, PhD, and colleagues found that current artificial intelligence (AI) algorithms that use "deep learning"—a type of machine learning that is based on artificial neural networks— outperform humans, even experts, in the classification of pigmented skin lesions . In this interview with i3 Health, Philipp Tschandl, member of the Vienna Dermatologic Imaging Research (ViDIR) Group of the Medical University of Vienna's Department of Dermatology, discusses the significance of the s...
Continue reading

Overall Survival for Pembrolizumab in Advanced NSCLC: Edward B. Garon, MD

Non-small cell lung cancer (NSCLC) has traditionally had a poor prognosis in terms of overall survival. This dismal outcome is changing, however: the phase 1 KEYNOTE-001 study found that pembrolizumab (Keytruda®, Merck) substantially increases five-year overall survival for patients with advanced NSCLC. In this interview with i3 Health, Edward B. Garon, MD, the study's lead investigator, discusses the trial's results and their implications for patients and physicians. Can you comment on the sign...
Continue reading

Ruxolitinib for Steroid-Refractory Acute GVHD: An Interview With Corey S. Cutler, MD, MPH, FRCPC

Recently, the FDA approved ruxolitinib (Jakafi®, Incyte Corporation), a JAK1/JAK2 inhibitor, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). A potentially life-threatening condition, GVHD is a complication of allogeneic hematopoietic stem cell transplantation (HSCT), a treatment for hematologic malignancies that is administered following high-intensity chemotherapy or radiation. In this interview with i3 Health, Corey S. Cutler, MD, MPH, FRCPC, Medical Director of...
Continue reading

Advising Patients on Follicular Lymphoma Treatment: An Interview With Carla Casulo, MD

Receiving a cancer diagnosis can be devastating, confusing, and overwhelming. It is important for oncologists to be thorough in explaining the treatment process to patients. In this interview with i3 Health, Carla Casulo, MD, Associate Professor at the University of Rochester Medical Center, gives advice on counseling patients diagnosed with follicular lymphoma. What questions do you commonly encounter from patients or caregivers about their treatment, and how do you counsel them? Carla Casulo, ...
Continue reading

Lenalidomide/Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma: John P. Leonard, MD

This week, the FDA approved lenalidomide (Revlimid®, Celgene Corporation) in combination with a rituximab product for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory marginal zone lymphoma (MZL). In this interview with i3 Health, John P. Leonard, MD, lead author of the AUGMENT trial, on which the approval was based, discusses the approval's importance and shares his advice for physicians treating patients with relapsed/refractory FL or MZL. Can you comment on the significanc...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.